ICD-O-3 to ICD-10 conversion for hemato-oncological diseases following recent updates in both classifications

Klaus Kraywinkel ¹, Nina Buttmann-Schweiger ¹, Miriam Holzmann ², Kirsten Schülke ³, Annie Funk ⁴, Doris Weinberger ⁵, Stefan W. Krause ⁶

¹ German Centre for Cancer Registry Data, Robert Koch Institute, Berlin; ² Cancer Registry of Schleswig-Holstein; ³ Cancer Registry of Hessen; ⁴ Cancer Registry of Hamburg; ⁵ Tumor Centre Regensburg; ⁶ University Clinic Erlangen, Dep. of Hematology and Oncology

BACKGROUND. The major update of WHO-ICD-10 classification introduced in 2010 resulted in substantial changes for hemato-oncological diseases by introducing a new 3-digit (C86) and several new 4-digit codes and terms. For a substantial number of codes an unambiguous (1:1) conversion within ICD-10 seemed impossible. Furthermore the conversion programs provided by IARC (ICD-O-3 to ICD-10) could no longer be used for these diagnoses.

Main purpose was to ensure the best possible METHODS. automated conversion of ICD-10 codes to the updated version for all hemato-oncological cases diagnosed until 2010, by making use of the typically more specific ICD-O-3 information. Therefore, we developed a new conversion table from ICD-O-3 to ICD-10 for ICD-O-3 morphology codes 9590/3 to 9989/3. Additionally, conversions for the new ICD-O-3 codes introduced in 2011 were provided. For the first draft of the conversion table, we used a systematic approach using a hierarchical structure of criteria, mainly based on synonym terms given in both classifications and additional information from the WHO Classification of tumours of Haematopoetic and Lymphoid Tissues. This draft was circulated among coding specialists in the registries, and finally all ambiguities were discussed with a clinical oncologist, member of the Topical Advisory Group for Neoplasm for the WHO (SWK).

RESULTS. All conversions are given in table 2. When applied to the pooled data of German cancer registries (2006-2010), 18% of hemato-oncological cases ICD-10 codes changed on the 4-digit, and 6% on the 3-digit level. Changes between major diagnostic groups (1.3%) or between C- and D-codes (0.2%) were rare. Nearly half of the 3-digit changes originated from the conversion of 9699/3 (marginal zone-B-cell-lymphoma n.o.s.) to C83.0 or C88.4 (depending on localization) instead of C82.7.



ROBERT KOCH INSTITUT

Table 1: Criteria used to derive ICD-O-3 to ICD-10 conversion (applied in hierarchical order from A. to H.)

- A Main title identical for both codes (applicable for 28 codes)
- B Main title for both codes are judged as synonym (40 codes)
- C Main title in ICD-O-3 is mentioned in the systematic directory of ICD-10 under this code (26 codes)
- D Synonym for the main titel in ICD-O-3 is mentioned in the systematic directory of ICD-10 under this code (11 codes)
- E Main title in ICD-O-3 is used as a synonym or inclusive term under this code in the alphabetical directory of ICD-10 (7 codes)
- F Generic term in ICD-O-3 ICD-O-3 (widely) identical to main title ICD-10, lower level of differentiation in ICD-10 (35 codes)
- G Use of inclusive terms from both classifications (2 codes)
- H No equivalent terms in ICD-O-3/ICD-10. Conversion derived from WHO classification or expert decision (SK) (15 codes)

Table 2a: Codes for automated conversion from ICD-O-3 to ICD-10 (lymphoma, plasma cell neoplasm and immunoproliferative diseases)

DISCUSSION. For a number of ICD-O-3 codes, no 1:1 conversion to ICD-10 was possible, and while we supply a reasonable solution for automated conversion, more accurate ICD-10 codes could be found when going back to diagnostic/pathologic reports. Some diagnostic terms are only used either in ICD-10 or ICD-O-3, which made conversion difficult and sometimes required arbitrary decisions. For Myeloma, the conversion was done with respect to common practice in Germany where 'Plasmacytoma' is often used as the more generic term (instead of Myeloma).

CONCLUSIONS. Despite limited impact on the data, we suggest the use of our conversion table (ICD-O-3 to ICD-10) for hemato-oncological diseases in population based cancer registries, especially for analyzing time trends according to ICD-10. The complete conversion table in electronic form can be ordered from our website (comments and suggestions welcome). For the future (ICD-11), an improved coordination between ICD and ICD-O working groups regarding hemato-oncological diseases is highly desirable.

Table 2b: Codes for automated conversion from ICD-O-3 to ICD-10 (leukemia and myelodysplastic/myeloproliferative diseases)

ICD-O-3 Code ICD-O-3 Morphology (Main title)	ICD-10 Code ICD-10 Title	ICD-O-3 Code ICD-O-3 Morphology (Main title)	ICD-10 Code ICD-10 Title
9590/3 Malignant lymphoma, NOS	C85.9 Non-Hodgkin lymphoma, unspecified	9800/3 Leukemia, NOS	C95.9 Leukaemia, unspecified
9591/3 Malignant lymphoma, non-Hodgkin, NOS	C85.9 Non-Hodgkin lymphoma, unspecified	9801/3 Acute leukemia, NOS	C95.0 Acute leukaemia of unspecified cell type
9596/3 Composite Hodgkin and non-Hodgkin lymphoma	C85.7 Other specified types of non-Hodgkin lymphoma	 9805/3 Acute biphenotypic leukemia 9806/3 Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1 	C95.0 Acute leukaemia of unspecified cell type
9597/3 Primary cutaneous follicle centre lymphoma 9650/3 Hodgkin lymphoma, NOS	C82.6 Cutaneous follicle centre lymphoma C81.9 Hodgkin lymphoma, unspecified	9807/3 Mixed phenotype acute leukemia with t(9,22)(q34,q11.2), BCR-ABLI 9807/3 Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged	C95.0 Acute leukaemia of unspecified cell type C95.0 Acute leukaemia of unspecified cell type
9651/3 Hodgkin lymphoma, lymphocyte-rich	C81.4 Lymphocyte-rich classical Hodgkin lymphoma	9808/3 Mixed phenotype acute leukemia, B/myeloid, NOS	C95.0 Acute leukaemia of unspecified cell type
9652/3 Hodgkin lymphoma, mixed cellularity, NOS	C81.2 Mixed cellularity classical Hodgkin lymphoma	9809/3 Mixed phenotype acute leukemia, T/myeloid, NOS	C95.0 Acute leukaemia of unspecified cell type
9653/3 Hodgkin lymphoma, lymphocyte depletion, NOS	C81.3 Lymphocyte depleted classical Hodgkin lymphoma	9811/3 B-lymphoblastic leukemia/lymphoma, NOS	C91.0 Acute lymphoblastic leukaemia [ALL]
9654/3 Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis	C81.3 Lymphocyte depleted classical Hodgkin lymphoma	9812/3 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1	C91.0 Acute lymphoblastic leukaemia [ALL]
9655/3 Hodgkin lymphoma, lymphocyte depletion, reticular	C81.3 Lymphocyte depleted classical Hodgkin lymphoma	9813/3 B-lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged	C91.0 Acute lymphoblastic leukaemia [ALL]
9659/3 Hodgkin lymphoma, nodular lymphocyte predominance	C81.0 Nodular lymphocyte predominant Hodgkin lymphoma	B-lymphoblastic leukemia/lymphoma with t(12;21) (p13;q22);	C91.0 Acute lymphoblastic leukaemia [ALL]
9661/3 Hodgkin granuloma	C81.9 Hodgkin lymphoma, unspecified	TEL-AIVILI (ETVO-RUNAT)	
9662/3 Hodgkin sarcoma	C81.3 Lymphocyte depleted classical Hodgkin lymphoma	9815/3 B-lymphoblastic leukemia/lymphoma with hyperdiploidy	C91.0 Acute lymphoblastic leukaemia [ALL]
9663/3 Hodgkin lymphoma, nodular sclerosis, NOS 9664/3 Hodgkin lymphoma, nodular sclerosis, cellular phase	C81.1 Nodular sclerosis classical Hodgkin lymphoma C81.1 Nodular sclerosis classical Hodgkin lymphoma	9816/3 B-lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)	C91.0 Acute lymphoblastic leukaemia [ALL]
9665/3 Hodgkin lymphoma, nodular sclerosis, grade 1	C81.1 Nodular sclerosis classical Hodgkin lymphoma	9817/3 B-lymphoblastic leukemia/lymphoma with t(5;14) (q31;q32); IL3-IGH	C91.0 Acute lymphoblastic leukaemia [ALL]
9667/3 Hodgkin lymphoma, nodular sclerosis, grade 2	C81.1 Nodular sclerosis classical Hodgkin lymphoma	9 ⁸¹⁸ /3 B-lymphoblastic leukemia/lymphoma with t(1;19) (q23;p13.3); E2A-PBX1 (TCF3- PBX1)	C91.0 Acute lymphoblastic leukaemia [ALL]
9670/3 Malignant lymphoma, small B lymphocytic, NOS	C83.0 Small cell B-cell lymphoma	9820/3 Lymphoid leukemia, NOS	C91.9 Lymphoid leukaemia, unspecified
9671/3 Malignant lymphoma, lymphoplasmacytic	C83.0 Small cell B-cell lymphoma	9823/3 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	C91.1 Chronic lymphocytic leukaemia of B-cell type
9673/3 Mantle cell lymphoma	C83.1 Mantle cell lymphoma	9826/3 Burkitt cell leukemia	C91.8 Mature B-cell leukaemia Burkitt-type
9675/3 Malignant lymphoma, mixed small and large cell, diffuse	C85.9 Non-Hodgkin lymphoma, unspecified	9827/3 Adult T-cell leukemia/lymphoma (HTLV-1 positive)	C91.5 Adult T-cell lymphoma/leukaemia (HTLV-1-associated)
9678/3 Primary effusion lymphoma	C83.8 Other non-follicular lymphoma	9831/1 T-cell large granular lymphocytic leukemia	C91.7 Other lymphoid leukaemia
9679/3 Mediastinal large B-cell lymphoma	C85.2 Mediastinal (thymic) large B-cell lymphoma	9831/3 T-cell large granular lymphocytic leukemia	C91.7 Other lymphoid leukaemia
9680/3 Malignant lymphoma, large B-cell, diffuse, NOS	C83.3 Diffuse large B-cell lymphoma	9832/3 Prolymphocytic leukemia, NOS	C91.3 Prolymphocytic leukaemia of B-cell type
9684/3 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS	C83.3 Diffuse large B-cell lymphoma	9833/3 Prolymphocytic leukemia, B-cell type	C91.3 Prolymphocytic leukaemia of B-cell type
9687/3 Burkitt lymphoma, NOS	C83.7 Burkitt lymphoma	9834/3 Prolymphocytic leukemia, T-cell type9835/3 Precursor cell lymphoblastic leukemia, NOS	C91.6 Prolymphocytic leukaemia of T-cell type C91.0 Acute lymphoblastic leukaemia [ALL]
9688/3 T-cell/histiocyte rich large B-cell lymphoma	C83.3 Diffuse large B-cell lymphoma	9836/3 Precursor B-cell lymphoblastic leukemia	C91.0 Acute lymphoblastic leukaemia [ALL]
9689/3 Splenic marginal zone B-cell lymphoma	C83.0 Small cell B-cell lymphoma	9837/3 Precursor T-cell lymphoblastic leukemia	C91.0 Acute lymphoblastic leukaemia [ALL]
9690/3 Follicular lymphoma, NOS	C82.9 Follicular lymphoma, unspecified	9840/3 Acute myeloid leukemia, M6 type	C94.0 Acute erythroid leukaemia
9691/3 Follicular lymphoma, grade 2	C82.1 Follicular lymphoma grade II	9860/3 Myeloid leukemia, NOS	C92.9 Myeloid leukaemia, unspecified
9695/3 Follicular lymphoma, grade 1	C82.0 Follicular lymphoma grade I	9861/3 Acute myeloid leukemia, NOS	C92.0 Acute myeloblastic leukaemia [AML]
9698/3 Follicular lymphoma, grade 3	C82.2 Follicular lymphoma grade III, unspecified	9863/3 Chronic myeloid leukemia, NOS	C92.1 Chronic myeloid leukaemia [CML], BCR/ABL-positive
9699/3 Marginal zone B-cell lymphoma, NOS*	C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue	9865/3 Acute myeloid leukemia with t(6;9) (p23;q34); DEK-NUP214	C92.0 Acute myeloblastic leukaemia [AML]
9699/3 Marginal zone B-cell lymphoma, NOS**	C83.0 Small cell B-cell lymphoma	9866/3 Acute promyelocytic leukemia	C92.4 Acute promyelocytic leukaemia [PML]
9700/3 Mycosis fungoides	C84.0 Mycosis fungoides	9867/3 Acute myelomonocytic leukemia	C92.5 Acute myelomonocytic leukaemia
9701/3 Sezary syndrome	C84.1 Sézary disease	9869/3 Acute myeloid leukemia with inv(3) ($q_{21}q_{26.2}$) or t(3;3) ($q_{21}q_{26.2}$); RPN1-EVI1	C92.0 Acute myeloblastic leukaemia [AML]
9702/3 Mature T-cell lymphoma, NOS	C84.4 Peripheral T-cell lymphoma, not classified	9870/3 Acute basophilic leukemia	C94.7 Other specified leukaemias
9705/3 Angioimmunoblastic T-cell lymphoma	C86.5 Angioimmunoblastic T-cell lymphoma	9871/3 Acute myeloid leukemia with abnormal marrow eosinophils	C92.5 Acute myelomonocytic leukaemia
9708/3 Subcutaneous panniculitis-like T-cell lymphoma	C86.3 Subcutaneous panniculitis-like T-cell lymphoma	9872/3 Acute myeloid leukemia, minimal differentiation	C92.0 Acute myeloblastic leukaemia [AML]
9709/3 Cutaneous T-cell lymphoma, NOS	C84.8 Cutaneous T-cell lymphoma, unspecified	9873/3 Acute myeloid leukemia without maturation	C92.0 Acute myeloblastic leukaemia [AML]
9712/3 Intravascular large B-cell lymphoma	C83.8 Other non-follicular lymphoma	9874/3 Acute myeloid leukemia with maturation	C92.0 Acute myeloblastic leukaemia [AML]
9714/3 Anaplastic large cell lymphoma, T cell and Null cell type	C84.6 Anaplastic large cell lymphoma, ALK-positive	9875/3 Chronic myelogenous leukemia, BCR/ABL positive	C92.1 Chronic myeloid leukaemia [CML], BCR/ABL-positive
9716/3 Hepatosplenic (gamma-delta) cell lymphoma 9717/3 Intestinal T-cell lymphoma	C86.1 Hepatosplenic T-cell lymphoma C86.2 Enteropathy-type (intestinal) T-cell lymphoma	9876/3 Atypical chronic myeloid leukemia, BCR/ABL negative	C92.2 Atypical chronic myeloid leukaemia, BCR/ABL- negative
9718/3 Primary cutaneous CD30+ T-cell lymphoproliferative disorder	C86.6 Primary cutaneous CD30-positive T-cell proliferations	9891/3 Acute monocytic leukemia	C93.0 Acute monoblastic/monocytic leukaemia
9719/3 NK/T-cell lymphoma, nasal and nasal-type	C86.0 Extranodal NK/T-cell lymphoma, nasal type	9895/3 Acute myeloid leukemia with multilineage dysplasia 9896/3 Acute myeloid leukemia, t(8;21) (q22;q22)	C92.8 Acute myeloid leukaemia with multilineage dysplasia C92.0 Acute myeloblastic leukaemia [AML]
Systemic EBV positive T-cell lymphoproliferative disease of		9897/3 Acute myeloid leukemia, 11q23 abnormalities	C92.6 Acute myeloid leukaemia with 11q23-abnormality
9724/3 childhood	C84.5 Other mature T/NK-cell lymphomas		Other specified neoplasms of uncertain or unknown behaviour of
9725/3 Hydroa vacciniforme-like lymphoma	C84.5 Other mature T/NK-cell lymphomas	9898/1 Transient abnormal myelopoiesis	D47.7 lymphoid, haematopoietic and related tissue
9726/3 Primary cutaneous gamma-delta T-cell lymphoma	C84.5 Other mature T/NK-cell lymphomas	9898/3 Myeloid leukemia associated with Down Syndrome	C92.0 Acute myeloblastic leukaemia [AML]
9727/3 Precursor cell lymphoblastic lymphoma, NOS	C83.5 Lymphoblastic (diffuse) lymphoma	9910/3 Acute megakaryoblastic leukemia	C94.2 Acute megakaryoblastic leukaemia
9728/3 Precursor B-cell lymphoblastic lymphoma	C83.5 Lymphoblastic (diffuse) lymphoma C83.5 Lymphoblastic (diffuse) lymphoma	9911/3 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1	C94.2 Acute megakaryoblastic leukaemia
9729/3 Precursor T-cell lymphoblastic lymphoma 9731/3 Plasmacytoma, NOS	C90.0 Multiple myeloma***		
9732/3 Multiple myeloma	C90.0 Multiple myeloma	9920/3 Therapy-related acute myeloid leukemia, NOS	C92.0 Acute myeloblastic leukaemia [AML]
9733/3 Plasma cell leukemia	C90.1 Plasma cell leukaemia	9930/3 Myeloid sarcoma 9931/3 Acute panmyelosis with myelofibrosis	C92.3 Myeloid sarcoma C94.4 Acute panmyelosis with myelofibrosis
9734/3 Plasmacytoma, extramedullary (not occurring in bone)	C90.2 Extramedullary plasmacytoma	9931/3 Acute parimyelosis with myelolibrosis 9940/3 Hairy cell leukemia	C94.4 Acute pannyelosis with myelolibrosis C91.4 Hairy-cell leukaemia
9735/3 Plasmablastic lymphoma	C83.3 Diffuse large B-cell lymphoma	9945/3 Chronic myelomonocytic leukemia, NOS	C93.1 Chronic myelomonocytic leukaemia
9737/3 ALK positive large B-cell lymphoma	C83.3 Diffuse large B-cell lymphoma	9946/3 Juvenile myelomonocytic leukemia	C93.3 Juvenile myelomonocytic leukaemia
4738/3 Large B-cell lymphoma arising in HHV8-associated multicentric	C83.3 Diffuse large B-cell lymphoma	9948/3 Aggressive NK-cell leukemia	C94.7 Other specified leukaemias
9738/3 Castleman disease		9950/3 Polycythemia vera	D45 Polycythaemia vera
9740/1 Mastocytoma, NOS	D47.0 Histiocytic and mast cell tumours of uncertain and unknown behaviour	9960/3 Chronic myeloproliferative disease, NOS	D47.1 Chronic myeloproliferative disease
9740/3 Mast cell sarcoma	C96.2 Malignant mast cell tumours of uncertain and unknown behaviour	9961/3 Myelosclerosis with myeloid metaplasia	D47.4 Osteomyelofibrosis
9741/1 Indolent systemic mastocytosis 9741/3 Malignant mastocytosis	D47.0 Histiocytic and mast cell tumours of uncertain and unknown behaviour C96.2 Malignant mast cell tumour	9962/3 Essential thrombocythemia	D47.3 Essential (haemorrhagic) thrombocythaemia
9747/3 Maignant mastocytosis 9742/3 Mast cell leukemia	C96.2 Manghant mast cen turnour C94.3 Mast cell leukaemia	9963/3 Chronic neutrophilic leukemia	D47.1 Chronic myeloproliferative disease
9750/3 Malignant histiocytosis	C96.8 Histiocytic sarcoma	9964/3 Hypereosinophilic syndrome 9965/3 Myeloid and lymphoid neoplasms with PDGFRA rearrangement	D47.5 Chronic eosinophilic leukaemia [hypereosinophilic syndrome] D47.1 Chronic myeloproliferative disease
9751/1 Langerhans cell histiocytosis, NOS	C96.6 Unifocal Langerhans-cell histiocytosis	9965/3 Myeloid and lymphoid neoplasms with PDGFRA rearrangement 9966/3 Myeloid neoplasms with PDGFRB rearrangement	D47.1 Chronic myeloproliferative disease D47.1 Chronic myeloproliferative disease
9751/3 Langerhans cell histiocytosis, NOS	C96.6 Unifocal Langerhans-cell histiocytosis	9967/3 Myeloid and lymphoid neoplasms with FGFR1 abnormalities	D47.1 Chronic myeloproliferative disease
9752/1 Langerhans cell histiocytosis, unifocal	C96.6 Unifocal Langerhans-cell histiocytosis		Neoplasm of uncertain or unknown behaviour of lymphoid
9753/1 Langerhans cell histiocytosis, multifocal	C96.5 Multifocal and unisystemic Langerhans-cell histiocytosis	9970/1 Lymphoproliferative disorder, NOS	D _{47.9} haematopoietic and related tissue, unspecified
9754/3 Langerhans cell histiocytosis, disseminated	C96.0 Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis	9971/1 Post transplant lymphoproliferative disorder, NOS	Other specified neoplasms of uncertain or unknown behaviour of
9755/3 Histiocytic sarcoma	C96.8 Histiocytic sarcoma		lymphoid, haematopoietic and related tissue
9756/3 Langerhans cell sarcoma	C96.4 Sarcoma of dendritic cells (accessory cells)	9971/3 Polymorphic post transplant lymphoproliferative disorder	C88.7 Other malignant immunoproliferative diseases
9757/3 Interdigitating dendritic cell sarcoma 9758/3 Follicular dendritic cell sarcoma	C96.4 Sarcoma of dendritic cells (accessory cells) C96.4 Sarcoma of dendritic cells (accessory cells)	9975/1 Myeloproliferative disease, NOS	D47.1 Chronic myeloproliferative disease
9758/3 Follicular dendritic cell sarcoma 9759/3 Fibroblastic reticular cell tumor	C96.4 Sarcoma of dendritic cells (accessory cells) C96.4 Sarcoma of dendritic cells (accessory cells)	9975/3 Myeloproliferative neoplasm, NOS	D47.1 Chronic myeloproliferative disease
9760/3 Immunoproliferative disease, NOS	C88.9 Malignant immunoproliferative disease, unspecified	9980/3 Refractory anemia 9982/3 Refractory anemia with sideroblasts	D46.4 Refractory anaemia, unspecified D46.1 Refractory anaemia with ringed sideroblasts
9761/3 Waldenstrom macroglobulinemia	C88.0 Waldenström macroglobulinaemia	9983/3 Refractory anemia with excess blasts	D46.2 Refractory anaemia with excess of blasts
9762/3 Heavy chain disease, NOS	C88.2 Other heavy chain disease	9984/3 Refractory anemia with excess blasts in transformation	C92.0 Acute myeloblastic leukaemia [AML]
9764/3 Immunoproliferative small intestinal disease	C88.3 Immunoproliferative small intestinal disease	9985/3 Refractory cytopenia with multilineage dysplasia	D46.5 Refractory anaemia with multi-lineage dysplasia
9765/1 Monoclonal gammopathy of undetermined significance	D47.2 Monoclonal gammopathy of undetermined significance (MGUS)	9986/3 Myelodysplastic syndrome with 5q deletion (5q-) syndrome	D46.6 Myelodysplastic syndrome with isolated del(5q) chromosomal
9766/1 Angiocentric immunoproliferative lesion	C86.0 Extranodal NK/T-cell lymphoma, nasal type		abnormanty
9767/1 Angioimmunoblastic lymphadenopathy (AIC)	C86.5 Angioimmunoblastic T-cell lymphoma	9987/3 Therapy-related myelodysplastic syndrome, NOS	D46.9 Myelodysplastic syndrome, unspecified
9768/1 T-gamma lymphoproliferative disease	C91.7 Other lymphoid leukaemia Other specified neoplasms of uncertain/unknown behaviour of lymphoid	9989/3 Myelodysplastic syndrome, NOS	D46.9 Myelodysplastic syndrome, unspecified
9769/1 Immunoglobulin deposition disease	D47.7 Other specified neoplasms of uncertain/unknown behaviour of lymphoid, haematopoietic and related tissue	9991/3 Refractory neutropenia	D46.7 Other myelodysplastic syndromes
	2.0. C/2.1. C/2.3. C/2.4. C77 *** For international use. C90.3 (Solitary plasmacytoma) might be co	9992/3 Refractory thrombocytopenia	D46.7 Other myelodysplastic syndromes

*Topography codes Coo-C41, C42.2, C43-C76, C80 ** Topography codes C42.0, C42.1, C42.3, C42.4, C77 *** For international use, C90.3 (Solitary plasmacytoma) might be considered

32th IACR-conference

Ottawa 24-29 June 2014

Homepage: www.krebsdaten.de

Contact: k.kraywinkel@rki.de